On May 3, 2021, Gemini Therapeutics, Inc. announced that Georges Gemayel, Ph.D. had been appointed to serve as a member of the Company’s Board of Directors (the “Board”), to fill the newly created vacancy on its Board. Mr. Gemayel will also serve as the Chairman of the Board. The Board determined that Mr. Gemayel is independent under the listing standards of NASDAQ and the Company’s corporate governance guidelines. Mr. Gemayel will serve as a Class III director with a term expiring at the annual meeting of stockholders to be held in 2023. Mr. Gemayel will be joining the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board.